| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5702505 | Urologic Oncology: Seminars and Original Investigations | 2017 | 7 Pages |
Abstract
Young patients treated with PN demonstrate an overall survival advantage. This survival advantage is observed after an early follow-up even in those without comorbidities. It is still not clear if the survival advantage seen is due to treatment itself or selection bias.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Daniel C. B.S., Kyle M.P.H., Telisa Dr.P.H., Dongliang Ph.D., Margaret Ph.D., Michael M.D., Gennady M.D.,